Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database
This study aimed to identify the components of proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) that lead to cardiovascular events in individuals of working age. We analyzed large claims data of individuals who were administered PPIs or PCAB. We enrolled working-age individ...
Gespeichert in:
| Veröffentlicht in: | Biological & pharmaceutical bulletin 2022/09/01, Vol.45(9), pp.1373-1377 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1377 |
|---|---|
| container_issue | 9 |
| container_start_page | 1373 |
| container_title | Biological & pharmaceutical bulletin |
| container_volume | 45 |
| creator | Watanabe, Ayako Momo, Kenji Tanaka, Katsumi Uchikura, Takeshi Kiryu, Yoshihiro Niiyama, Kanami Kodaira, Norihisa Matsuzaki, Airi Sasaki, Tadanori |
| description | This study aimed to identify the components of proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) that lead to cardiovascular events in individuals of working age. We analyzed large claims data of individuals who were administered PPIs or PCAB. We enrolled working-age individuals administered PPI or PCAB without cardiovascular history with a 12-month screening and 12-month observation period and determined the proportion of cardiovascular events and the predictive factors of cardiovascular events in this population. Among the eligible individuals, 0.5% (456/91098) had cardiovascular events during the 12-month observation period. Predictive factors for cardiovascular events were age for +1 year (p |
| doi_str_mv | 10.1248/bpb.b22-00367 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2709016608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2709016608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-8e611f485487ab9b3fd5f9c69499c9501188467358392ef26c442719a56444653</originalsourceid><addsrcrecordid>eNpdkUGP0zAUhCMEEmXhyP1JXLhksRPHibmVsEClIirYFcfoxXEadxM7azuV9v_yQ3BbtAcutuz55o2tSZK3lFzTjFUf2rm9brMsJSTn5bNkRXNWpkVGi-fJighapZwW1cvklfcHQkhJsnyV_Nl0ygTda4lBWwO2hzAoqO00WxMVf7rZORuitlumGTZm0K0O1nlA08HOBvReL1N6sqiggz4qWEvdwafRynvl4HbAAFuFHQQLNbpO2yN6uYzo4OZ4ztAGflt3r80-Xe9VzOj0UXcLjv4jrIFm6XdrwgA_VXDWz0qeQ2o7WBfgV1i6R7jz0QwIW3RxQD2injx8xoAtevU6edHHWerNv_0quftyc1t_S7c_vm7q9TaVrCpDWilOac-qIp6wFW3ed0UvJBdMCCkKQmlVMV7mRZWLTPUZl4xlJRVYcMYYL_Kr5P1l7uzsw6J8aCbtpRpHNMouvslKIgjlnFQRffcferCLM_F1F6oUJT9R6YWS8d_eqb6ZnZ7QPTaUNKfOm9h5Eztvzp1Hvr7wBx9wr55odEHLUZ1pVjTitDy5nlQ5oGuUyf8C0Sa5XQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2709079768</pqid></control><display><type>article</type><title>Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database</title><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Watanabe, Ayako ; Momo, Kenji ; Tanaka, Katsumi ; Uchikura, Takeshi ; Kiryu, Yoshihiro ; Niiyama, Kanami ; Kodaira, Norihisa ; Matsuzaki, Airi ; Sasaki, Tadanori</creator><creatorcontrib>Watanabe, Ayako ; Momo, Kenji ; Tanaka, Katsumi ; Uchikura, Takeshi ; Kiryu, Yoshihiro ; Niiyama, Kanami ; Kodaira, Norihisa ; Matsuzaki, Airi ; Sasaki, Tadanori</creatorcontrib><description>This study aimed to identify the components of proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) that lead to cardiovascular events in individuals of working age. We analyzed large claims data of individuals who were administered PPIs or PCAB. We enrolled working-age individuals administered PPI or PCAB without cardiovascular history with a 12-month screening and 12-month observation period and determined the proportion of cardiovascular events and the predictive factors of cardiovascular events in this population. Among the eligible individuals, 0.5% (456/91098) had cardiovascular events during the 12-month observation period. Predictive factors for cardiovascular events were age for +1 year (p < 0.0001), male sex (p < 0.0001), hypertension (p = 0.0056), and diabetes mellitus (p < 0.0001). The cardiovascular disease risk was higher in working-age individuals administered lansoprazole than in those administered other drugs (vs. rabeprazole; p = 0.0002, vs. omeprazole; p = 0.0046, vs. vonoprazan; p < 0.0001, and vs. esomeprazole; p < 0.0001). We identified the risk for cardiovascular events in individuals being treated with lansoprazole. Lansoprazole is known for its higher CYP2C19 inhibition activity compared with other PPIs or PCAB. A possible mechanism by which lansoprazole may lead to cardiovascular events is inhibiting the generation of epoxyeicosatrienoic acids from arachidonic acids, an intrinsic cardioprotective activator via CYP2C19 inhibition. Thus, we recommend avoiding administering lansoprazole to working-age individuals require PPIs or PCAB.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b22-00367</identifier><language>eng</language><publisher>Tokyo: The Pharmaceutical Society of Japan</publisher><subject>Age ; cardiovascular disease ; Cardiovascular diseases ; claim-data ; Cohort analysis ; Diabetes mellitus ; Omeprazole ; Potassium ; potassium-competitive acid blocker ; proton pump inhibitor ; Proton pump inhibitors</subject><ispartof>Biological and Pharmaceutical Bulletin, 2022/09/01, Vol.45(9), pp.1373-1377</ispartof><rights>2022 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-8e611f485487ab9b3fd5f9c69499c9501188467358392ef26c442719a56444653</citedby><cites>FETCH-LOGICAL-c487t-8e611f485487ab9b3fd5f9c69499c9501188467358392ef26c442719a56444653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,1884,27929,27930</link.rule.ids></links><search><creatorcontrib>Watanabe, Ayako</creatorcontrib><creatorcontrib>Momo, Kenji</creatorcontrib><creatorcontrib>Tanaka, Katsumi</creatorcontrib><creatorcontrib>Uchikura, Takeshi</creatorcontrib><creatorcontrib>Kiryu, Yoshihiro</creatorcontrib><creatorcontrib>Niiyama, Kanami</creatorcontrib><creatorcontrib>Kodaira, Norihisa</creatorcontrib><creatorcontrib>Matsuzaki, Airi</creatorcontrib><creatorcontrib>Sasaki, Tadanori</creatorcontrib><title>Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database</title><title>Biological & pharmaceutical bulletin</title><description>This study aimed to identify the components of proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) that lead to cardiovascular events in individuals of working age. We analyzed large claims data of individuals who were administered PPIs or PCAB. We enrolled working-age individuals administered PPI or PCAB without cardiovascular history with a 12-month screening and 12-month observation period and determined the proportion of cardiovascular events and the predictive factors of cardiovascular events in this population. Among the eligible individuals, 0.5% (456/91098) had cardiovascular events during the 12-month observation period. Predictive factors for cardiovascular events were age for +1 year (p < 0.0001), male sex (p < 0.0001), hypertension (p = 0.0056), and diabetes mellitus (p < 0.0001). The cardiovascular disease risk was higher in working-age individuals administered lansoprazole than in those administered other drugs (vs. rabeprazole; p = 0.0002, vs. omeprazole; p = 0.0046, vs. vonoprazan; p < 0.0001, and vs. esomeprazole; p < 0.0001). We identified the risk for cardiovascular events in individuals being treated with lansoprazole. Lansoprazole is known for its higher CYP2C19 inhibition activity compared with other PPIs or PCAB. A possible mechanism by which lansoprazole may lead to cardiovascular events is inhibiting the generation of epoxyeicosatrienoic acids from arachidonic acids, an intrinsic cardioprotective activator via CYP2C19 inhibition. Thus, we recommend avoiding administering lansoprazole to working-age individuals require PPIs or PCAB.</description><subject>Age</subject><subject>cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>claim-data</subject><subject>Cohort analysis</subject><subject>Diabetes mellitus</subject><subject>Omeprazole</subject><subject>Potassium</subject><subject>potassium-competitive acid blocker</subject><subject>proton pump inhibitor</subject><subject>Proton pump inhibitors</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkUGP0zAUhCMEEmXhyP1JXLhksRPHibmVsEClIirYFcfoxXEadxM7azuV9v_yQ3BbtAcutuz55o2tSZK3lFzTjFUf2rm9brMsJSTn5bNkRXNWpkVGi-fJighapZwW1cvklfcHQkhJsnyV_Nl0ygTda4lBWwO2hzAoqO00WxMVf7rZORuitlumGTZm0K0O1nlA08HOBvReL1N6sqiggz4qWEvdwafRynvl4HbAAFuFHQQLNbpO2yN6uYzo4OZ4ztAGflt3r80-Xe9VzOj0UXcLjv4jrIFm6XdrwgA_VXDWz0qeQ2o7WBfgV1i6R7jz0QwIW3RxQD2injx8xoAtevU6edHHWerNv_0quftyc1t_S7c_vm7q9TaVrCpDWilOac-qIp6wFW3ed0UvJBdMCCkKQmlVMV7mRZWLTPUZl4xlJRVYcMYYL_Kr5P1l7uzsw6J8aCbtpRpHNMouvslKIgjlnFQRffcferCLM_F1F6oUJT9R6YWS8d_eqb6ZnZ7QPTaUNKfOm9h5Eztvzp1Hvr7wBx9wr55odEHLUZ1pVjTitDy5nlQ5oGuUyf8C0Sa5XQ</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Watanabe, Ayako</creator><creator>Momo, Kenji</creator><creator>Tanaka, Katsumi</creator><creator>Uchikura, Takeshi</creator><creator>Kiryu, Yoshihiro</creator><creator>Niiyama, Kanami</creator><creator>Kodaira, Norihisa</creator><creator>Matsuzaki, Airi</creator><creator>Sasaki, Tadanori</creator><general>The Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20220901</creationdate><title>Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database</title><author>Watanabe, Ayako ; Momo, Kenji ; Tanaka, Katsumi ; Uchikura, Takeshi ; Kiryu, Yoshihiro ; Niiyama, Kanami ; Kodaira, Norihisa ; Matsuzaki, Airi ; Sasaki, Tadanori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-8e611f485487ab9b3fd5f9c69499c9501188467358392ef26c442719a56444653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>claim-data</topic><topic>Cohort analysis</topic><topic>Diabetes mellitus</topic><topic>Omeprazole</topic><topic>Potassium</topic><topic>potassium-competitive acid blocker</topic><topic>proton pump inhibitor</topic><topic>Proton pump inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watanabe, Ayako</creatorcontrib><creatorcontrib>Momo, Kenji</creatorcontrib><creatorcontrib>Tanaka, Katsumi</creatorcontrib><creatorcontrib>Uchikura, Takeshi</creatorcontrib><creatorcontrib>Kiryu, Yoshihiro</creatorcontrib><creatorcontrib>Niiyama, Kanami</creatorcontrib><creatorcontrib>Kodaira, Norihisa</creatorcontrib><creatorcontrib>Matsuzaki, Airi</creatorcontrib><creatorcontrib>Sasaki, Tadanori</creatorcontrib><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watanabe, Ayako</au><au>Momo, Kenji</au><au>Tanaka, Katsumi</au><au>Uchikura, Takeshi</au><au>Kiryu, Yoshihiro</au><au>Niiyama, Kanami</au><au>Kodaira, Norihisa</au><au>Matsuzaki, Airi</au><au>Sasaki, Tadanori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><date>2022-09-01</date><risdate>2022</risdate><volume>45</volume><issue>9</issue><spage>1373</spage><epage>1377</epage><pages>1373-1377</pages><artnum>b22-00367</artnum><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>This study aimed to identify the components of proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) that lead to cardiovascular events in individuals of working age. We analyzed large claims data of individuals who were administered PPIs or PCAB. We enrolled working-age individuals administered PPI or PCAB without cardiovascular history with a 12-month screening and 12-month observation period and determined the proportion of cardiovascular events and the predictive factors of cardiovascular events in this population. Among the eligible individuals, 0.5% (456/91098) had cardiovascular events during the 12-month observation period. Predictive factors for cardiovascular events were age for +1 year (p < 0.0001), male sex (p < 0.0001), hypertension (p = 0.0056), and diabetes mellitus (p < 0.0001). The cardiovascular disease risk was higher in working-age individuals administered lansoprazole than in those administered other drugs (vs. rabeprazole; p = 0.0002, vs. omeprazole; p = 0.0046, vs. vonoprazan; p < 0.0001, and vs. esomeprazole; p < 0.0001). We identified the risk for cardiovascular events in individuals being treated with lansoprazole. Lansoprazole is known for its higher CYP2C19 inhibition activity compared with other PPIs or PCAB. A possible mechanism by which lansoprazole may lead to cardiovascular events is inhibiting the generation of epoxyeicosatrienoic acids from arachidonic acids, an intrinsic cardioprotective activator via CYP2C19 inhibition. Thus, we recommend avoiding administering lansoprazole to working-age individuals require PPIs or PCAB.</abstract><cop>Tokyo</cop><pub>The Pharmaceutical Society of Japan</pub><doi>10.1248/bpb.b22-00367</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-6158 |
| ispartof | Biological and Pharmaceutical Bulletin, 2022/09/01, Vol.45(9), pp.1373-1377 |
| issn | 0918-6158 1347-5215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2709016608 |
| source | J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
| subjects | Age cardiovascular disease Cardiovascular diseases claim-data Cohort analysis Diabetes mellitus Omeprazole Potassium potassium-competitive acid blocker proton pump inhibitor Proton pump inhibitors |
| title | Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T03%3A41%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20the%20Components%20of%20Proton%20Pump%20Inhibitors%20and%20Potassium-Competitive%20Acid%20Blocker%20That%20Lead%20to%20Cardiovascular%20Events%20in%20Working-Age%20Individuals:%20A%2012-Month%20Retrospective%20Cohort%20Study%20Using%20a%20Large%20Claims%20Database&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Watanabe,%20Ayako&rft.date=2022-09-01&rft.volume=45&rft.issue=9&rft.spage=1373&rft.epage=1377&rft.pages=1373-1377&rft.artnum=b22-00367&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b22-00367&rft_dat=%3Cproquest_cross%3E2709016608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2709079768&rft_id=info:pmid/&rfr_iscdi=true |